Alnylam Pharmaceuticals Inc (ALNY)vsMesoblast Ltd (MESO)
ALNY
Alnylam Pharmaceuticals Inc
$286.41
-0.19%
HEALTHCARE · Cap: $37.76B
MESO
Mesoblast Ltd
$15.50
-6.56%
HEALTHCARE · Cap: $1.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 6457% more annual revenue ($4.29B vs $65.38M). ALNY leads profitability with a 12.6% profit margin vs -144.3%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
MESO
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2363.38
Current Price
$286.41
$2076.97 discount
Margin of Safety
+44.1%
Fair Value
$32.74
Current Price
$15.50
$17.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Revenue surging 1527.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 35.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -18.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MESO
The strongest argument for MESO centers on Revenue Growth, Debt/Equity. Revenue growth of 1527.0% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : MESO
The primary concerns for MESO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ALNY profiles as a growth stock while MESO is a hypergrowth play — different risk/reward profiles.
MESO carries more volatility with a beta of 0.79 — expect wider price swings.
MESO is growing revenue faster at 1527.0% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 25/100) and 96.4% revenue growth. MESO offers better value entry with a 44.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Mesoblast Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?